Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2410MR)

This product GTTS-WQ2410MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2410MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13248MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ1657MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ14685MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ10578MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ1432MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ12386MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ3577MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ4025MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW